# KLOW Blend > Source: https://chooseunscripted.com/peptide/klow-blend/ > Content type: Peptide research profile > Last updated: September 4, 2026 **For research use only. Not for human or veterinary use.** ## Scientific / Common Name KLOW Peptide Blend ## Alternative Names / Synonyms KLOW Blend · KLOW Peptide Blend · KLOW ## Molecular Formula Blend — not applicable ## Molecular Weight Blend — not applicable ## CAS Number Blend — not applicable ## Clinical Development Phase Not Established ## Regulatory Status KLOW is not an FDA-approved drug or an established clinical formulation. Its individual components have differing research and regulatory histories. ## Peptide Classification Multi-Peptide Research Blend ## Primary Research Focus Tissue repair and regeneration; wound-healing and extracellular matrix remodeling; angiogenesis and vascular response; inflammatory signaling and immune modulation; cellular migration and repair processes; and gastrointestinal tissue-protection pathways. ## Mechanism Summary KLOW combines four research peptides with distinct proposed biological activities rather than acting through a single defined receptor or mechanism. GHK-Cu has been investigated in relation to extracellular matrix remodeling, wound-response signaling, angiogenesis, and gene expression. BPC-157 has been studied experimentally in tissue-repair and vascular-response models. TB-500 is associated with research involving thymosin beta-4–related pathways, including actin regulation, cell migration, and tissue repair. KPV, a tripeptide derived from α-melanocyte-stimulating hormone, has been investigated for effects on inflammatory signaling. These mechanistic observations largely derive from research on the individual components. They should not be interpreted as demonstrating that the combined KLOW formulation produces the same effects. ## Evidence Summary The components of KLOW have substantially different evidence bases. GHK-Cu has been investigated in laboratory and clinical research involving skin biology, wound repair, extracellular matrix regulation, and related processes. KPV has a body of preclinical research examining inflammatory pathways. BPC-157 has primarily been investigated in preclinical models, while human evidence remains limited. Research involving TB-500 should also be distinguished from research on the naturally occurring thymosin beta-4 molecule from which related peptide fragments are derived. Evidence concerning the individual ingredients does not establish the safety, efficacy, pharmacology, or clinical effects of the four-component KLOW blend. The combined formulation should therefore be described as a research blend rather than as a clinically validated therapeutic combination. ## Key References **GHK-Cu** Pickart L. *The human tri-peptide GHK and tissue remodeling.* Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969–988. DOI: 10.1163/156856208784909435. [View on PubMed](https://pubmed.ncbi.nlm.nih.gov/18644225/?utm_source=chatgpt.com) Supports discussion of GHK-Cu in extracellular-matrix remodeling, inflammatory processes, angiogenesis, and tissue-repair research. **BPC-157** Gwyer D, et al. *Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.* Cell and Tissue Research. 2019;377:153–159. [View on PubMed](https://pubmed.ncbi.nlm.nih.gov/30915550/?utm_source=chatgpt.com) A useful critical review of BPC-157 research involving tendon, ligament, skeletal muscle, and other soft-tissue models. The authors specifically note that most evidence comes from small-animal studies and that efficacy had not been confirmed in humans. **Thymosin β4 / TB-500-related research** Goldstein AL, Hannappel E, Kleinman HK. *Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues.* Trends in Molecular Medicine. 2005;11(9):421–429. DOI: 10.1016/j.molmed.2005.07.004. [View on PubMed](https://pubmed.ncbi.nlm.nih.gov/16099219/?utm_source=chatgpt.com) Reviews thymosin β4’s biochemical properties, actin interaction, and research concerning tissue repair and remodeling. **KPV** Brzoska T, et al. *Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.* Endocrine Reviews. 2008;29(5):581–602. [View on PubMed](https://pubmed.ncbi.nlm.nih.gov/18612139/?utm_source=chatgpt.com) Reviews α-MSH-related pathways and KPV specifically, including experimental evidence involving inflammatory signaling. **KPV — experimental model** Kannengiesser K, et al. *Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.* Inflammatory Bowel Diseases. 2008;14(3):324–331. DOI: 10.1002/ibd.20334. [View on PubMed](https://pubmed.ncbi.nlm.nih.gov/18092346/?utm_source=chatgpt.com) Provides direct preclinical research on KPV in murine inflammatory models. **Evidence note:** References above concern the individual components of the KLOW formulation. They do not establish the safety, efficacy, or biological effects of the combined KLOW blend. ## Last Scientifically Reviewed August 10, 2026 ## Quick Definition KLOW is an 80mg multi-peptide research blend containing GHK-Cu, BPC-157, TB-500, and KPV. Its individual components have been investigated across tissue repair, extracellular matrix remodeling, angiogenic, inflammatory signaling, and cellular-response pathways. The KLOW combination itself has not been established as a clinically validated formulation. ## Targets / Receptors Multiple molecular targets and signaling pathways associated with GHK-Cu, BPC-157, thymosin beta-4–related peptides, and KPV, including pathways involved in tissue remodeling, angiogenesis, inflammatory signaling, and cellular repair responses. ## Safety & Limitations Published evidence does not establish the safety, efficacy, dosing, pharmacokinetics, or long-term effects of the KLOW combination in humans. Evidence concerning individual components varies considerably in quality and clinical relevance and cannot be assumed to apply to the combined formulation. KLOW is intended for research use only and is not intended for human consumption, diagnosis, treatment, cure, or prevention of disease. ## Frequently Asked Questions - ### What is KLOW? KLOW is a multi-peptide research blend containing GHK-Cu, BPC-157, TB-500, and KPV. The 80mg formulation contains 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500, and 10mg KPV. The individual components have been investigated across tissue repair, extracellular matrix remodeling, inflammatory signaling, angiogenesis, and cellular-response pathways. - ### What peptides are included in the KLOW 80mg blend? The KLOW 80mg research blend contains GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg), and KPV (10mg). Each component has a distinct research history and proposed biological activity, and evidence concerning an individual component should not be assumed to apply to the combined formulation. - ### What is KLOW being researched for? Research relevant to KLOW's individual components includes tissue repair and regeneration, wound-healing processes, extracellular matrix remodeling, angiogenesis and vascular response, inflammatory signaling, immune modulation, cellular migration, and gastrointestinal tissue-protection pathways. The KLOW combination itself has not been established as a clinically validated therapeutic formulation. - ### How does the KLOW peptide blend work? KLOW does not have a single established mechanism of action. Its four components are associated with different biological pathways. GHK-Cu has been investigated in extracellular matrix remodeling, angiogenesis, and wound-response signaling; BPC-157 in experimental tissue-repair and vascular models; TB-500 in thymosin beta-4-related pathways involving actin regulation and cell migration; and KPV in inflammatory signaling. Research on these individual mechanisms does not establish the pharmacological effects of the combined KLOW formulation. - ### Does KLOW have a molecular formula or CAS number? KLOW does not have a single molecular formula, molecular weight, or CAS number because it is a blend of four separate peptides rather than one chemical entity. GHK-Cu, BPC-157, TB-500, and KPV each have their own chemical characteristics and identifiers. - ### Is KLOW approved for human use? No. KLOW is not an FDA-approved drug or an established clinical formulation. Published evidence does not establish the safety, efficacy, dosing, pharmacokinetics, or long-term effects of the combined KLOW formulation in humans. Products supplied by Unscripted are intended for research use only and are not intended for human consumption. ## Product URL ## Blend Composition GHK-Cu 50mg · BPC-157 10mg · TB-500 10mg · KPV 10mg ## Multi-Compound Blend Yes ## Available Research Compound - [Product page](https://chooseunscripted.com/shop/klow-blend/index.md)